Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Caribou Biosciences

Main focus: Next generation allogeneic CAR-T and CAR-natural killer (NK) cell therapies

Company stage: Clinical

Diseases: Non-hodgkins lymphoma (NHL), multiple myeloma (MM), acute myeloid leukaemia (AML)

Genome editing tool: CRISPR-Cas9, CRISPR-Cas12a

Funding stage: Public (NASDAQ:CRBU)

Location: Berkeley, CA, USA



Partners: Abbvie, ProMab Biotechnologies, MaxCyte

Caribou Biosciences develops novel allogeneic CAR-T and CAR-NK cell therapies. It uses CRISPR-Cas9 and CRISPR-Cas12a to knock out multiple genes, such as TRAC (endogenous T cell receptor) in healthy donor-derived T cells, and PD-1 and B2M to armor the cells. The company is testing its CB010 programme, directed towards CD19, in early clinical trials. Caribou is also developing multiple pre-clinical assets. The company is co-founded by Nobel prize winner, Jennifer Doudna.


HashtagCaribou Biosciences, Inc.

Company: Caribou Biosciences
Search CRISPR Medicine